A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
Completed · Phase 3 · NCT04470427
Conditions: SARS-CoV-2
At a glance
- Research payments reported, 2025
- $922
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30,415
About the trial
- Sponsor
- ModernaTX, Inc. (with Biomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases (NIAID))
- Tested
- mRNA-1273 (biological), Placebo (biological)
- Dates
- Started 2020-07-27; completion 2022-12-29
- Results posted
- Yes
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
From ClinicalTrials.gov, last updated 2024-03-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $922 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $922
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.